The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Outcomes in patients with double refractory DLBCL receiving third-line CD19 CAR-T therapy
In this video, John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, shares insights into a study evaluating the implications of third-line CD19 CAR T-cell therapy in patients with double refractory diffuse large B-cell lymphoma (DLBCL). Dr Kuruvilla notes that a high rate of patients were unable to proceed to CAR T-cell therapy, highlighting the need to improve outcomes for this population. Despite reassuring outcomes in patients who did receive CAR-T, results suggest that outcomes may not be as good as expected. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
